A protein-vaccine developer with no fresh catalyst just posted a double-digit gain that dwarfs what Moderna and Merck managed in the same session, and the explanation reveals something uncomfortable about how this…
Pfizer's dividend yield has climbed well above what most blue-chip drugmakers offer, and the reason behind that gap matters far more than the number itself.
Cantor Fitzgerald just bumped price targets on Eli Lilly, AbbVie, Merck, and Pfizer, but higher targets do not mean equal conviction. The firm's split between Overweight and Neutral ratings reveals a sharp…
On October 7, three companies with nothing in common sent cash to their shareholders, but the differences in what each paid, how fast each raised it, and what the stock price does…
Three stocks left the S&P 500's 2025 return in the dust, but gains that large raise one uncomfortable question: is the opportunity already gone, or does one of them still have a…
Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are trading as though the company’s messenger RNA (mRNA) cancer vaccine has already cleared its final test, even though the complete Phase 3 dataset…
Ten consecutive earnings beats and a shrinking COVID hangover have Wall Street split on whether Pfizer deserves a breakout or a ceiling, and the answer hinges on a single pipeline deal that…
Eli Lilly just posted a 47.7% revenue surge while rivals like Novo Nordisk are watching earnings fall, and a fresh pipeline catalyst could push Lilly toward a valuation Wall Street has only…
Both JNJ and MRK have surged in 2026, but a looming patent cliff and a balance sheet loaded with acquisition debt mean one of these pharma dividends faces a reckoning that retirement…
Buyers are stepping into Moderna (NASDAQ:MRNA | MRNA Price Prediction) shares, evidently. The move comes one session after a Citigroup (NYSE:C) downgrade to Sell, a sign the market still prizes the company’s…
Moderna (NASDAQ:MRNA | MRNA Price Prediction) stock is drawing attention Wednesday after Citigroup downgraded the biotech company to Sell from Hold, arguing that the recent rally has pushed the valuation well ahead…
Eli Lilly is growing faster than any other mega-cap drugmaker, but a pipeline drug still awaiting approval and falling U.S. prices are pulling the stock in opposite directions. The outcome of that…
Merck spent most of a decade trailing the S&P 500, then something unusual happened in a single year that changed the entire math. Whether that burst signals a new chapter or a…
Chris Lange Johnson & Johnson's oncology and immunology pipeline is firing on multiple cylinders, but a collapsing blockbuster drug and mounting litigation costs threaten to cancel out every gain. Here is whether the bull…
Holding blue-chip Dow dividend payers in a taxable account quietly hands the IRS a cut of every reinvested dollar, year after year, and the compounding cost over two decades is far steeper…
